Trials / Enrolling By Invitation
Enrolling By InvitationNCT07055607
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,250 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study. |
Timeline
- Start date
- 2025-11-21
- Primary completion
- 2028-08-15
- Completion
- 2028-08-15
- First posted
- 2025-07-09
- Last updated
- 2026-03-05
Locations
16 sites across 3 countries: Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT07055607. Inclusion in this directory is not an endorsement.